top of page
Recruiting: Open

Eczema Cream Study

Clinical Trial

Preparing for Blood Test
Description
  • Randomised double-blinded study

  • 2 study groups 

    • ​Ruxolitinib cream 1.5% 

    • Vehicle cream

  • Participants randomised into the vehicle cream treatment arm will be allowed to enter the ruxolitinib 1.5% cream open-label escape arm after 8 weeks if treatment is inadequate.

Trial length

34 Weeks

Participant age

Participant ages can range from 18 and above

Patient eligibility
  • Participants must have atopic dermatitis (AD) for 2 or more years

  • Participants must have moderate AD

  • Participants must have history (within 12 months before the screening visit) of inadequate response, intolerance, or contraindication to topical corticosteroids and topical calcineurin inhibitors

  • Female participants must NOT be pregnant 

10 onsite visits are required from patients

*Travel is reimbursed for each visit

Follow-up inclusions

Objectives

To establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to topical corticosteroids and topical calcineurin inhibitors.

Interested in participating?

Send us a message or give us a call here

Description
  • Randomised double-blinded study

  • 2 study groups 

    • Ruxolitinib cream 1.5% 

    • Vehicle cream

  • Participants randomised into the vehicle cream treatment arm will be allowed to enter the ruxolitinib 1.5% cream open-label escape arm after 8 weeks if treatment is inadequate.

Trial length

34 weeks

Participant age

Participant ages can range from 18 and above.

Patient eligibility
  • Participants must have atopic dermatitis (AD) for 2 or more years

  • Participants must have moderate AD

  • Participants must have history (within 12 months before the screening visit) of inadequate response, intolerance, or contraindication to topical corticosteroids and topical calcineurin inhibitors

  • Female participants must NOT be pregnant 

10 onsite visits are required from patients

*Travel is reimbursed for each visit

Follow-up inclusions

Objectives

To establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to topical corticosteroids and topical calcineurin inhibitors.

Interested in participating?

Send us a message or give us a call here

Recruiting: Open

Eczema Cream Study

Clinical Trial

iStock-1746826952.jpg

Got questions?

Read our common queries about clinical trials, participation processes, safety measures, and more.

Get in touch with us

Our friendly team would love to hear from you! 

bottom of page